
    
      Study Design: This is a Phase 1, first-in-human (FIH), open-label, multicenter, multicohort
      study of LB1901 administered to adult subjects with histologically confirmed CD4+ relapsed or
      refractory Peripheral T-cell lymphoma (PTCL) (PTCL not otherwise specified [PTCL-NOS] and
      angioimmunoblastic [AITL]), or relapsed or refractory cutaneous T-cell lymphoma (CTCL)
      (SÃ©zary syndrome [SS] and mycosis fungoides [MF]).
    
  